Table 2 Safety summary (safety population)
Characteristic | Powder formulation (n = 14) | Caplet formulation (n = 14) |
|---|---|---|
Participants with ≥ TEAE, n (%) | 1 (7.1) | 2 (14.3) |
TEAEs, n | 1 | 3 |
Discontinuations due to TEAEs, n (%) | 0 | 0 |
Treatment-related TEAEs, n (%) | 1 (7.1) | 1 (7.1) |
SAEs, n (%) | 0 | 0 |
Deaths, n (%) | 0 | 0 |
TEAEs by preferred term, n (%) | ||
Diarrhea | 0 | 1 (7.1) |
Fatigue | 1 (7.1) | 0 |
Increased ALT level | 0 | 1 (7.1) |
Nausea | 0 | 1 (7.1) |